^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    allogeneic Myeloma GM-CSF Vaccine

    i
    Other names: allogeneic GVAX myeloma vaccine, allogeneic myeloma vaccine with GM-CSF-secreting K562 cells, GVAX allogeneic myeloma vaccine, MM-GVAX, allogeneic Myeloma GM-CSF Vaccine, allogeneic GM-CSF-secreting multiple myeloma vaccine
    Associations

    News

    Trials
    Company:
    Sidney Kimmel Comprehensive Cancer Center
    Drug class:
    Immunostimulant, GM-CSF agonist
    Related drugs:
    Associations

    News

    Trials
    2ms
    Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov)
    P2, N=54, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2024 --> Dec 2024
    Trial completion date
    |
    lenalidomide • allogeneic Myeloma GM-CSF Vaccine